Abstract
Heart failure, or congestive heart failure, is a condition in which the heart cannot supply the body's tissues with enough blood. The result is a cascade of changes that lead to severe fatigue, breathlessness and, ultimately, death. In the past quarter century, much progress has been made in understanding the molecular and cellular processes that contribute to heart failure, leading to the development of effective therapies. Despite this, chronic heart failure remains a major cause of illness and death. And because the condition becomes more common with increasing age, the number of affected individuals is rising with the rapidly ageing global population. New treatments that target disease mechanisms at the cellular and whole-organ level are needed to halt and reverse the devastating consequences of this disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fnature06798/MediaObjects/41586_2008_Article_BFnature06798_Fig1_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fnature06798/MediaObjects/41586_2008_Article_BFnature06798_Fig2_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fnature06798/MediaObjects/41586_2008_Article_BFnature06798_Fig3_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fnature06798/MediaObjects/41586_2008_Article_BFnature06798_Fig4_HTML.jpg)
Similar content being viewed by others
References
Lutz, J. E. A XII century description of congestive heart failure. Am. J. Cardiol. 61, 494–495 (1988).
Rosamond, W. et al. Heart disease and stroke statistics — 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117, e25–e146 (2008).
Packer, M. et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N. Engl. J Med. 325, 1468–1475 (1991).
Cohn, J. N. et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N. Engl. J. Med. 311, 819–823 (1984).
Wettschureck, N. et al. Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Gαq/Gα11 in cardiomyocytes. Nature Med. 7, 1236–1240 (2001).
Yan, L. et al. Type 5 adenylyl cyclase disruption increases longevity and protects against stress. Cell 130, 247–258 (2007).
White, D. C. et al. Preservation of myocardial β-adrenergic receptor signaling delays the development of heart failure after myocardial infarction. Proc. Natl Acad. Sci. USA 97, 5428–5433 (2000).
Lai, N. C. et al. Intracoronary adenovirus encoding adenylyl cyclase VI increases left ventricular function in heart failure. Circulation 110, 330–336 (2004).
Heineke, J. & Molkentin, J. D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nature Rev. Mol. Cell Biol. 7, 589–600 (2006).
Perrino, C. et al. Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. J. Clin. Invest. 116, 1547–1560 (2006).
Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 341, 709–717 (1999).
Pfeffer, M. A. et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N. Engl. J. Med. 327, 669–677 (1992). This was one of the first trials to show that, in patients with heart failure, neurohormonal suppression improves the rates of morbidity and mortality.
Packer, M. et al. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 344, 1651–1658 (2001).
Brodde, O. E. β-Adrenoceptor blocker treatment and the cardiac β-adrenoceptor–G-protein(s)–adenylyl cyclase system in chronic heart failure. Naunyn Schmiedebergs Arch. Pharmacol. 374, 361–372 (2007).
Lowes, B. D. et al. Myocardial gene expression in dilated cardiomyopathy treated with β-blocking agents. N. Engl. J. Med. 346, 1357–1365 (2002).
Xiao, R. P. β-Adrenergic signaling in the heart: dual coupling of the β2-adrenergic receptor to Gs and Gi proteins. Sci. STKE 2001, RE15, doi:10.1126/stke.2001.104.re15 (2001).
Noma, T. et al. β-Arrestin-mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J. Clin. Invest. 117, 2445–2458 (2007).
Mann, D. L. et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109, 1594–1602 (2004).
Forfia, P. R. et al. Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J. Am. Coll. Cardiol. 49, 1079–1088 (2007).
Morita, H., Seidman, J. & Seidman, C. E. Genetic causes of human heart failure. J. Clin. Invest. 115, 518–526 (2005).
Boheler, K. R. et al. Sex- and age-dependent human transcriptome variability: implications for chronic heart failure. Proc. Natl Acad. Sci. USA 100, 2754–2759 (2003).
Taylor, A. L. et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N. Engl. J. Med. 351, 2049–2057 (2004).
Liggett, S. B. et al. The Ile164 β2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J. Clin. Invest. 102, 1534–1539 (1998).
Wagoner, L. E. et al. Polymorphisms of the β2-adrenergic receptor determine exercise capacity in patients with heart failure. Circ. Res. 86, 834–840 (2000).
Small, K. M., Wagoner, L. E., Levin, A. M., Kardia, S. L. & Liggett, S. B. Synergistic polymorphisms of β1- and α2C-adrenergic receptors and the risk of congestive heart failure. N. Engl. J. Med. 347, 1135–1142 (2002).
Liggett, S. B. et al. A polymorphism within a conserved β1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure. Proc. Natl Acad. Sci. USA 103, 11288–11293 (2006).
Mialet, P. J. et al. β1-Adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nature Med. 9, 1300–1305 (2003). This study describes how a β 1 -AR polymorphism (arginine at position 389) in animal models and humans affects adrenergic signalling in heart failure and affects the response to therapy.
Liggett, S. B. et al. A functional polymorphism of the Gαq (GNAQ) gene is associated with accelerated mortality in African American heart failure. Hum. Mol. Genet. 16, 2740–2750 (2007).
McKinsey, T. A. & Kass, D. A. Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nature Rev. Drug Discov. 6, 617–635 (2007).
Molkentin, J. D. et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93, 215–228 (1998). This paper shows the importance of Ca2+-dependent calcineurin activation in the development of hypertrophy and heart failure.
Zhang, R. et al. Calmodulin kinase II inhibition protects against structural heart disease. Nature Med. 11, 409–417 (2005).
Braz, J. C. et al. PKC-α regulates cardiac contractility and propensity toward heart failure. Nature Med. 10, 248–254 (2004).
Liao, P. et al. The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc. Natl Acad. Sci. USA 98, 12283–12288 (2001).
Hardt, S. E. & Sadoshima, J. Glycogen synthase kinase-3β: a novel regulator of cardiac hypertrophy and development. Circ. Res. 90, 1055–1063 (2002).
Antos, C. L. et al. Activated glycogen synthase-3β suppresses cardiac hypertrophy in vivo. Proc. Natl Acad. Sci. USA 99, 907–912 (2002).
Hirotani, S. et al. Inhibition of glycogen synthase kinase 3β during heart failure is protective. Circ. Res. 101, 1164–1174 (2007).
Schwartzbauer, G. & Robbins, J. The tumor suppressor gene PTEN can regulate cardiac hypertrophy and survival. J. Biol. Chem. 276, 35786–35793 (2001).
Trivedi, C. M. et al. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3β activity. Nature Med. 13, 324–331 (2007).
Zhai, P. et al. Glycogen synthase kinase-3α reduces cardiac growth and pressure overload-induced cardiac hypertrophy by inhibition of extracellular signal-regulated kinases. J. Biol. Chem. 282, 33181–33191 (2007).
van der, H. A. & Burgering, B. M. Stressing the role of FoxO proteins in lifespan and disease. Nature Rev. Mol. Cell Biol. 8, 440–450 (2007).
Hofmann, F., Feil, R., Kleppisch, T. & Schlossmann, J. Function of cGMP-dependent protein kinases as revealed by gene deletion. Physiol. Rev. 86, 1–23 (2006).
Takimoto, E. et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nature Med. 11, 214–222 (2005). This study shows that the PDE5 inhibitor sildenafil can stimulate cGMP–PKG signalling and thereby reverse cardiac remodelling induced by pressure overload.
Kass, D. A., Champion, H. C. & Beavo, J. A. Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ. Res. 101, 1084–1095 (2007).
Zhang, C. L. et al. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110, 479–488 (2002).
McKinsey, T. A., Zhang, C. L. & Olson, E. N. Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5. Proc. Natl Acad. Sci. USA 97, 14400–14405 (2000).
McKinsey, T. A., Zhang, C. L., Lu, J. & Olson, E. N. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature 408, 106–111 (2000).
Oka, T. et al. Cardiac-specific deletion of Gata4 reveals its requirement for hypertrophy, compensation, and myocyte viability. Circ. Res. 98, 837–845 (2006).
Care, A. et al. MicroRNA-133 controls cardiac hypertrophy. Nature Med. 13, 613–618 (2007).
Van Rooij, E. et al. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 316, 575–579 (2007). This paper shows that a miRNA encoded in an intron of the α-myosin heavy chain gene is responsible for regulating cardiac hypertrophy, fibrosis and β-myosin heavy chain production in response to stress-induced signalling.
Yang, B. et al. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nature Med. 13, 486–491 (2007).
Krutzfeldt, J. et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 438, 685–689 (2005).
Ebert, M. S., Neilson, J. R. & Sharp, P. A. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nature Methods 4, 721–726 (2007).
Takimoto, E. & Kass, D. A. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 49, 241–248 (2007).
Takimoto, E. et al. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J. Clin. Invest. 115, 1221–1231 (2005).
Foo, R. S., Mani, K. & Kitsis, R. N. Death begets failure in the heart. J. Clin. Invest. 115, 565–571 (2005).
Wencker, D. et al. A mechanistic role for cardiac myocyte apoptosis in heart failure. J. Clin. Invest. 111, 1497–1504 (2003). This paper shows that cardiac-restricted overproduction of an active caspase results in dilated cardiomyopathy, highlighting the role of apoptosis in the development of heart failure.
Hilfiker-Kleiner, D., Hilfiker, A. & Drexler, H. Many good reasons to have STAT3 in the heart. Pharmacol. Ther. 107, 131–137 (2005).
Shiraishi, I. et al. Nuclear targeting of Akt enhances kinase activity and survival of cardiomyocytes. Circ. Res. 94, 884–891 (2004).
Nakayama, H. et al. Ca2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. J. Clin. Invest. 117, 2431–2444 (2007).
Zhu, H. et al. Cardiac autophagy is a maladaptive response to hemodynamic stress. J. Clin. Invest. 117, 1782–1793 (2007).
Nakai, A. et al. The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nature Med. 13, 619–624 (2007).
Gnecchi, M. et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nature Med. 11, 367–368 (2005).
Bers, D. M. Altered cardiac myocyte Ca regulation in heart failure. Physiology (Bethesda) 21, 380–387 (2006).
Miyamoto, M. I. et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc. Natl Acad. Sci. USA 97, 793–798 (2000).
Pathak, A. et al. Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ. Res. 96, 756–766 (2005).
Marx, S. O. et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101, 365–376 (2000). This study shows that calstabin 2 regulates RYR2-mediated Ca2+ release from the sarcoplasmic reticulum and that hyperphosphorylation of calstabin 2 by PKA contributes to the defective regulation of RYR2.
Yano, M. et al. FKBP12.6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure. Circulation 107, 477–484 (2003).
Curran, J., Hinton, M. J., Rios, E., Bers, D. M. & Shannon, T. R. β-Adrenergic enhancement of sarcoplasmic reticulum calcium leak in cardiac myocytes is mediated by calcium/calmodulin-dependent protein kinase. Circ. Res. 100, 391–398 (2007).
Wehrens, X. H. et al. Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science 304, 292–296 (2004).
Balijepalli, R. C., Foell, J. D., Hall, D. D., Hell, J. W. & Kamp, T. J. Localization of cardiac L-type Ca2+ channels to a caveolar macromolecular signaling complex is required for β2-adrenergic regulation. Proc. Natl Acad. Sci. USA 103, 7500–7505 (2006).
Frey, N. et al. Mice lacking calsarcin-1 are sensitized to calcineurin signaling and show accelerated cardiomyopathy in response to pathological biomechanical stress. Nature Med. 10, 1336–1343 (2004).
Wu, X. et al. Local InsP3-dependent perinuclear Ca2+ signaling in cardiac myocyte excitation–transcription coupling. J. Clin. Invest. 116, 675–682 (2006). This paper describes how hypertrophy-mediated gene regulation can be controlled by Ca2+ microdomains, which are insulated from the global fluctuations in Ca2+ concentrations that are associated with excitation–contraction coupling.
Ohba, T. et al. Upregulation of TRPC1 in the development of cardiac hypertrophy. J. Mol. Cell. Cardiol. 42, 498–507 (2007).
Onohara, N. et al. TRPC3 and TRPC6 are essential for angiotensin II-induced cardiac hypertrophy. EMBO J. 25, 5305–5316 (2006).
Kuwahara, K. et al. TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. J. Clin. Invest. 116, 3114–3126 (2006).
Winn, M. P. et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 308, 1801–1804 (2005).
Lehman, J. J. et al. Peroxisome proliferator-activated receptor γ coactivator-1 promotes cardiac mitochondrial biogenesis. J. Clin. Invest. 106, 847–856 (2000). This study shows that PGC1 is a crucial regulator of cardiac mitochondrial function during normal growth and stress-induced states.
Vega, R. B., Huss, J. M. & Kelly, D. P. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor α in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol. Cell. Biol. 20, 1868–1876 (2000).
Arany, Z. et al. Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-γ coactivator 1α. Proc. Natl Acad. Sci. USA 103, 10086–10091 (2006).
Davila-Roman, V. G. et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J. Am. Coll. Cardiol. 40, 271–277 (2002).
Taha, M. & Lopaschuk, G. D. Alterations in energy metabolism in cardiomyopathies. Ann. Med. 39, 594–607 (2007).
Abozguia, K., Clarke, K., Lee, L. & Frenneaux, M. Modification of myocardial substrate use as a therapy for heart failure. Nature Clin. Pract. Cardiovasc. Med. 3, 490–498 (2006).
Weiss, R. G., Gerstenblith, G. & Bottomley, P. A. ATP flux through creatine kinase in the normal, stressed, and failing human heart. Proc. Natl Acad. Sci. USA 102, 808–813 (2005).
Shiojima, I. et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J. Clin. Invest. 115, 2108–2118 (2005).
Heineke, J. et al. Cardiomyocyte GATA4 functions as a stress-responsive regulator of angiogenesis in the murine heart. J. Clin. Invest. 117, 3198–3210 (2007).
Sano, M. et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 446, 444–448 (2007). This paper shows that p53 is important in the transition from hypertrophy to heart failure, through its antiangiogenic effects on HIF1α signalling, highlighting the importance of matching myocardial blood supply to tissue growth in progressive cardiac remodelling.
Lowes, B. D. et al. Changes in gene expression in the intact human heart. Downregulation of α-myosin heavy chain in hypertrophied, failing ventricular myocardium. J. Clin. Invest. 100, 2315–2324 (1997).
Hayashi, T. et al. Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy. J. Am. Coll. Cardiol. 44, 2192–2201 (2004).
Knoll, R. et al. The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell 111, 943–955 (2002).
Granzier, H. L. & Labeit, S. The giant protein titin: a major player in myocardial mechanics, signaling, and disease. Circ. Res. 94, 284–295 (2004).
Nagueh, S. F. et al. Altered titin expression, myocardial stiffness, and left ventricular function in patients with dilated cardiomyopathy. Circulation 110, 155–162 (2004).
Peng, J. et al. Cardiac hypertrophy and reduced contractility in hearts deficient in the titin kinase region. Circulation 115, 743–751 (2007).
Kass, D. A. & Solaro, R. J. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation 113, 305–315 (2006).
Spragg, D. D. & Kass, D. A. Pathobiology of left ventricular dyssynchrony and resynchronization. Prog. Cardiovasc. Dis. 49, 26–41 (2006).
Chakir, K. et al. Reversal of global apoptosis and regional stress kinase activation by cardiac resynchronization. Circulation (in the press).
Moss, A. J. et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N. Engl. J. Med. 346, 877–883 (2002).
Heerdt, P. M. et al. Chronic unloading by left ventricular assist device reverses contractile dysfunction and alters gene expression in end-stage heart failure. Circulation 102, 2713–2719 (2000).
Birks, E. J. et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N. Engl. J. Med. 355, 1873–1884 (2006).
Imai, M. et al. Therapy with cardiac contractility modulation electrical signals improves left ventricular function and remodeling in dogs with chronic heart failure. J. Am. Coll. Cardiol. 49, 2120–2128 (2007).
Li, M. et al. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 109, 120–124 (2004).
Acknowledgements
The authors thank the National Institutes of Health for financial support.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
D.A.K. is a founder of, and a scientific adviser to, Cardioxyl Pharmaceuticals, a start-up company developing nitroxyl (HNO) for the treatment of heart failure. He is also a scientific adviser to Boston Scientific, NanoCor Therapeutics and Cytokinetics. J.O.M. declares no competing interests.
Additional information
Correspondence should be addressed to D.A.K. (dkass@jhmi.edu).
Rights and permissions
About this article
Cite this article
Mudd, J., Kass, D. Tackling heart failure in the twenty-first century. Nature 451, 919–928 (2008). https://doi.org/10.1038/nature06798
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature06798
This article is cited by
-
Relationship between heart failure and intestinal inflammation in infants with congenital heart disease
BMC Microbiology (2024)
-
Network pharmacology and molecular docking analysis on Shenfu Qiangxin indicate mTOR is a potential target to treat heart failure
European Journal of Medical Research (2024)
-
Renal denervation reverses ventricular structural and functional remodeling in failing rabbit hearts
Scientific Reports (2023)
-
Fibroblast growth factor 18 alleviates stress-induced pathological cardiac hypertrophy in male mice
Nature Communications (2023)
-
Effect of injection of different doses of isoproterenol on the hearts of mice
BMC Cardiovascular Disorders (2022)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.